DOSE OF REALITY: Big Pharma’s True Track Record Is A Hard Pill To Swallow – Part II

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend – and why their rhetoric rings hollow when measured against their companies’ track record.

We’re taking a look at the unkept pledges, proclamations and promises made by Big Pharma that lawmakers should be prepared to confront with a “dose of reality.”

Last week, we examined the record of AbbVie compared to the rhetoric of CEO Richard Gonzalez.

Today, we will look at the rhetoric of AstraZeneca CEO Pascal Soriot compared to his company’s track record.




Pascal’s Pledges:










Stay tuned for our next blog tomorrow comparing another pharma CEO’s rhetoric to the reality. In the meantime:

CLICK HERE to read Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part I.

CLICK HERE to read about the real impact Big Pharma’s price gouging is having on patients across the country.


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.